American Society of Hematology

Figure 1.

$Figure 1. TTP. (A) TTP by histopathology in the 25 patients who progressed during venetoclax therapy. (B-D) The associations between TTP for patients with CLL/SLL receiving venetoclax therapy and (B) depth of clinical response: CR vs PR (P = .002) and PR vs SD (P < .001); (C) F-refractoriness (P = .005); and (D) karyotypic complexity (complex vs not complex; P = .005). In panel B, data from the whole cohort of n = 67 are presented. In panels C-D, only data from patients who received ≥400 mg/d are presented to exclude the response-modifying effect of use of low-dose venetoclax. Log-rank testing was used for comparisons. HR, hazard ratio.$

TTP. (A) TTP by histopathology in the 25 patients who progressed during venetoclax therapy. (B-D) The associations between TTP for patients with CLL/SLL receiving venetoclax therapy and (B) depth of clinical response: CR vs PR (P = .002) and PR vs SD (P < .001); (C) F-refractoriness (P = .005); and (D) karyotypic complexity (complex vs not complex; P = .005). In panel B, data from the whole cohort of n = 67 are presented. In panels C-D, only data from patients who received ≥400 mg/d are presented to exclude the response-modifying effect of use of low-dose venetoclax. Log-rank testing was used for comparisons. HR, hazard ratio.

This Feature Is Available To Subscribers Only